Extending the targets for antihypertensive drugs.
D
D
Bonn
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000502:physiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D019808:Losartan / Q000494:pharmacology; D015260:Neprilysin / Q000037:antagonists & inhibitors; D012084:Renin-Angiotensin System / Q000187:drug effects; D014667:Vasopressins / Q000037:antagonists & inhibitors / Q000502:physiology; D000092502:Renin Inhibitors
D000804:Angiotensin II; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019332:Endothelin-1; D004791:Enzyme Inhibitors; D019808:Losartan; D015260:Neprilysin; D014667:Vasopressins; D000092502:Renin Inhibitors